Every new obesity drug eventually has to answer a question that has nothing to do with the bathroom scale: does it increase the risk of heart attacks, strokes or other serious cardiovascular events?
For survodutide, Boehringer Ingelheim’s experimental once-weekly injection that activates both the GLP-1 receptor and the glucagon receptor, a major part of that question has now been answered.
On November 9, 2026, researchers published the results of SYNCHRONIZE-CVOT, a Phase 3 cardiovascular safety trial involving 5,530 randomized adults with overweight or obesity and elevated cardiovascular risk, in The Lancet.
The findings were presented the same day at the American Heart Association Scientific Sessions in Chicago.
Survodutide met the trial’s prespecified cardiovascular safety requirement. The rate of major cardiovascular events was not significantly different from placebo, providing reassurance about a drug mechanism that combines the familiar actions of GLP-1 with the more complicated biology of glucagon.
But the safety result came with a second finding that may prove just as important to clinicians and regulators.
Approximately one in five participants receiving survodutide discontinued treatment because of gastrointestinal side effects, compared with fewer than one in 50 receiving placebo.
The trial therefore delivered two different messages. The cardiovascular data were reassuring. The tolerability data showed why an effective medicine can still be difficult for patients to continue taking.
What the SYNCHRONIZE-CVOT Heart Safety Trial Tested
SYNCHRONIZE-CVOT was a randomized, double-blind, placebo-controlled Phase 3 trial conducted at 524 clinical sites across 34 countries.
Investigators enrolled adults aged 18 or older with a body mass index of at least 27 and established cardiovascular disease or at least two obesity-related complications or cardiovascular risk factors.
People with chronic kidney disease could also participate if their BMI was at least 30.
Enrollment ran from November 20, 2023, through November 8, 2024. Of 7,753 people screened, 5,530 were randomized, and 5,507 received at least one dose of study treatment.
The treated population was divided into three groups.
There were 1,836 participants assigned to survodutide titrated up to 3.6 mg weekly, 1,835 assigned to survodutide titrated up to 6.0 mg weekly, and 1,836 assigned to placebo.
All treatments were given by subcutaneous injection once a week.
The median time participants spent in the study was 22 months.
The primary outcome was not weight loss. Researchers measured the time until the first occurrence of any event in a five-part cardiovascular composite.
Those events were cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, coronary revascularization related to ischemia, or a heart failure event.
Unlike a study designed to demonstrate superiority, SYNCHRONIZE-CVOT was structured as a non-inferiority trial.
Its goal was to establish that survodutide did not increase cardiovascular risk beyond a predefined acceptable threshold compared with placebo.
The statistical threshold was an upper confidence-limit margin of 1.65 for the hazard ratio, with the two survodutide dose groups pooled for the primary analysis.
In other words, the investigators needed sufficient evidence to exclude a level of cardiovascular harm that exceeded the prespecified margin.
That design matters because demonstrating acceptable cardiovascular safety is not the same scientific task as demonstrating that a drug prevents cardiovascular events.
What the Survodutide Cardiovascular Results Actually Showed
Across the two survodutide groups, the primary cardiovascular endpoint occurred in 136 of 3,671 participants, or 3.7%.
In the placebo group, the endpoint occurred in 76 of 1,836 participants, or 4.1%.
The estimated hazard ratio was 0.89, with a 95% confidence interval from 0.67 to 1.18.
Because the upper confidence limit was below the predefined margin of 1.65, survodutide met the primary non-inferiority requirement.
The reported p-value for non-inferiority was below 0.0001.
But that p-value does not mean the drug reduced cardiovascular events compared with placebo.
The confidence interval crossed 1.0, the value representing no difference in hazard between groups. The results are therefore compatible with some cardiovascular benefit, no meaningful difference, or a modest increase in risk.
The trial established non-inferiority under its prespecified statistical definition. It did not establish cardiovascular superiority.
A hazard ratio of 0.89, with a confidence interval crossing 1.0, is evidence for the trial’s safety conclusion. It is not proof that survodutide protects the heart.
A secondary analysis examined the more familiar three-part cardiovascular composite of cardiovascular death, nonfatal stroke and nonfatal myocardial infarction.
For that outcome, the reported hazard ratio was 0.84, with a 95% confidence interval of 0.60 to 1.18.
That result also satisfied the prespecified non-inferiority requirement, but did not establish a statistically significant reduction in cardiovascular events.
The study reported additional improvements in cardiometabolic markers, including systolic blood pressure, waist circumference and body weight.
At 72 weeks, the supplementary secondary estimand, which estimates effects under continued treatment without certain treatment interruptions, showed body-weight reduction of up to 13.7% with survodutide compared with 2.0% with placebo.
Systolic blood pressure fell by up to 6.68 mmHg with survodutide compared with 1.76 mmHg on placebo, while waist circumference declined by up to 11.96 cm versus 2.74 cm.
Those findings provide evidence of favorable changes in several cardiovascular risk markers.
However, changes in weight, blood pressure and waist circumference should not be substituted for demonstrated reductions in heart attacks, strokes or cardiovascular death.
The endpoints answer different questions, and the study’s various statistical estimands should not be treated as interchangeable.
Why Glucagon Made Cardiovascular Safety So Important
Survodutide differs from medicines that activate only the GLP-1 receptor.
It is a dual agonist designed to activate both GLP-1 and glucagon receptors, two signaling pathways involved in metabolic regulation.
GLP-1 receptor activation can reduce appetite, slow gastric emptying and improve glucose regulation.
Glucagon receptor activation has different effects, including actions involving hepatic metabolism and energy expenditure.
That combination is one reason drug developers have pursued GLP-1/glucagon dual agonists for obesity and metabolic liver disease.
But glucagon has a complicated scientific history.
For decades, the hormone was commonly associated with raising blood glucose, making it seem like an unlikely component of a diabetes or obesity treatment.
As Grey Pepper examined in its profile of Roger Unger and the history of glucagon research, understanding the hormone’s wider role in metabolism required challenging assumptions about how it should be targeted.
Modern dual agonists attempt to combine complementary receptor activities in one molecule while maintaining a clinically acceptable safety profile.
Cardiovascular safety is particularly important because glucagon signaling can influence cardiac physiology, including heart rate, and patients receiving obesity treatments may already have substantial cardiovascular risk.
That made a dedicated cardiovascular outcomes trial relevant rather than merely a regulatory formality.
SYNCHRONIZE-CVOT provides substantial randomized human evidence that the tested survodutide regimens did not exceed the trial’s prespecified cardiovascular risk margin over the observation period.
It does not establish that every GLP-1/glucagon dual agonist has an identical cardiovascular profile.
Different molecules have different receptor potencies, dosing regimens, pharmacokinetics and tolerability characteristics.
The findings are therefore relevant to the wider drug-development field without serving as proof of cardiovascular safety for every related medicine.
Survodutide Side Effects: Nearly One in Five Patients Stopped Treatment
The cardiovascular results were the trial’s primary purpose. The gastrointestinal adverse-event data may be the more difficult commercial and clinical finding.
Nausea occurred in 48.0% of participants receiving 3.6 mg of survodutide and 49.0% receiving 6.0 mg.
In the placebo group, 12.1% reported nausea.
Vomiting was also substantially more common with active treatment.
It occurred in 31.7% of participants assigned to 3.6 mg and 34.0% assigned to 6.0 mg, compared with 4.8% receiving placebo.
Diarrhea and constipation were among the other commonly reported gastrointestinal adverse events.
The researchers described these events as generally mild to moderate in severity, but their effect on treatment continuation was substantial.
Gastrointestinal adverse events led to discontinuation in 19.3% of participants receiving survodutide 3.6 mg and 20.8% receiving 6.0 mg, versus 1.9% on placebo.
In absolute numbers, that represented 354 participants in the lower-dose group, 381 in the higher-dose group and 34 in the placebo group.
These discontinuation figures include gastrointestinal adverse events generally. They should not be interpreted as meaning every affected patient stopped specifically because of nausea or vomiting.
The distinction matters because an adverse event can be classified as mild or moderate and still make continuing treatment unacceptable to an individual patient.
Serious adverse events were reported in 22.5% of the 3.6 mg group, 20.8% of the 6.0 mg group and 23.9% of the placebo group.
Fatal adverse events were reported in 0.9% of participants in each survodutide group and 0.6% of those receiving placebo.
Those descriptive differences should not be interpreted as definitive evidence of a mortality effect, particularly given the relatively small numbers and the trial’s primary cardiovascular safety objective.
The proportion remaining on assigned treatment until study closeout was also relatively low across all three groups.
That figure was 56.0% on survodutide 3.6 mg, 56.6% on 6.0 mg and 59.0% on placebo.
Not every treatment interruption was caused by gastrointestinal symptoms. The trial’s overall persistence figures reflect a broader set of reasons for treatment discontinuation.
Nevertheless, the approximately 20% gastrointestinal discontinuation rates in the active-treatment groups represent a substantial tolerability burden.
A medicine cannot deliver its intended long-term benefit to patients who cannot tolerate staying on it.
The finding is consistent with the wider tension seen in survodutide’s development program: meaningful weight loss accompanied by gastrointestinal effects that require careful dose management.
Grey Pepper has previously examined this relationship in its coverage of survodutide’s Phase 3 weight-loss and side-effect findings.
Why Dose Escalation Complicates the Discontinuation Numbers
Boehringer Ingelheim offered an important qualification when announcing the results on November 9.
According to the company, gastrointestinal discontinuations generally occurred during dose escalation.
The original study protocol provided limited flexibility for managing adverse events through slower titration, dose adjustments or longer temporary treatment interruptions.
That matters because GLP-1-based medicines are often introduced gradually to help patients adjust to gastrointestinal effects.
If a protocol limits the ability to remain at a lower dose or delay an increase, some participants may discontinue treatment who might otherwise have continued under a more flexible schedule.
Boehringer says upcoming studies, including SYNCHRONIZE-START, SYNCHRONIZE-HERA, ELEVATE-LIVER and SYNCHRONIZE-T2D, incorporate more flexible, patient-centered titration strategies.
That is a plausible approach to improving treatment persistence.
But it is important to distinguish the company’s explanation from a proven solution.
SYNCHRONIZE-CVOT does not demonstrate how much lower discontinuation would have been under a different dose-escalation protocol.
Only subsequent studies can establish whether additional flexibility meaningfully improves persistence without compromising treatment efficacy or introducing different safety concerns.
Another methodological distinction is relevant.
The primary cardiovascular analysis used a treatment-regimen estimand, meaning that clinical outcomes were assessed regardless of whether participants stopped their assigned treatment, temporarily interrupted it, or used certain additional medications.
That is an appropriate method for evaluating outcomes associated with assigning a treatment strategy, including the real possibility that participants do not remain on therapy.
However, it also means the primary analysis does not exclusively describe cardiovascular events during uninterrupted exposure to survodutide.
The company reported that the trial also met its non-inferiority objective under a supplementary secondary estimand, providing an additional perspective on the cardiovascular results.
The distinction reinforces why trial designs, treatment persistence and statistical methods all matter when evaluating the safety of medicines intended for long-term use.
What the Results Mean for Survodutide and the Obesity Drug Market
For Boehringer Ingelheim and its development partner Zealand Pharma, SYNCHRONIZE-CVOT removes a major source of uncertainty surrounding the cardiovascular safety of survodutide.
The company has indicated that it is moving forward with global regulatory submissions for obesity, drawing on the broader SYNCHRONIZE clinical development program.
As of November 11, 2026, survodutide remains investigational and is not approved for clinical use.
The cardiovascular trial should be viewed alongside other Phase 3 evidence, rather than as a standalone demonstration of the medicine’s overall value.
For example, the randomized SYNCHRONIZE-1 obesity trial, published in the New England Journal of Medicine in June 2026, found mean body-weight reductions of 12.2% with survodutide 3.6 mg and 13.0% with 6.0 mg at week 76 under the treatment-regimen estimand, compared with 5.4% on placebo.
Those results support survodutide’s weight-loss efficacy in the population studied, while the cardiovascular trial addresses an important safety requirement in a different, higher-risk population.
Survodutide is also under development for metabolic dysfunction-associated steatohepatitis, or MASH, including studies involving liver fibrosis and compensated cirrhosis.
The drug’s dual receptor mechanism is attractive partly because it may affect several interconnected aspects of metabolic disease.
But its eventual position in clinical practice will depend on more than receptor biology or maximum observed weight loss.
Regulators will examine the complete efficacy and safety profile, including cardiovascular outcomes, adverse events, treatment discontinuation and the ability to manage dosing.
Clinicians will also have to consider how survodutide compares with established therapies in practice.
SYNCHRONIZE-CVOT did not directly compare survodutide with semaglutide, tirzepatide or another active obesity medicine.
It therefore cannot establish that survodutide has better cardiovascular safety, greater clinical benefit or superior tolerability than those drugs.
It also does not resolve whether survodutide provides direct cardiovascular protection beyond showing that it passed the trial’s non-inferiority threshold.
The results are nevertheless significant for the wider field of GLP-1/glucagon dual agonists, because they provide a large randomized human dataset addressing cardiovascular safety for this particular receptor combination.
That may support confidence in investigating related mechanisms, although other medicines will still need to establish their own safety and efficacy profiles.
The practical next question is whether future titration strategies can reduce gastrointestinal discontinuations enough to make survodutide a more sustainable long-term treatment.
The cardiovascular question received a reassuring answer. The adherence question remains open.
SYNCHRONIZE-CVOT was designed to answer a specific safety question, and it met that objective. Over a median 22 months, survodutide did not exceed the prespecified cardiovascular risk margin compared with placebo.
That is meaningful evidence for a drug that combines GLP-1 and glucagon receptor activation.
But the gastrointestinal findings are too substantial to treat as a minor footnote.
Around one in five treated participants stopped because of gastrointestinal adverse events, and only a little over half remained on their assigned treatment until study closeout.
For a medicine intended to manage a chronic condition, treatment persistence is not simply a convenience issue. It influences whether patients can continue receiving the intended benefits.
The next stage of development must establish whether those discontinuation rates can be improved and whether the drug’s advantages remain compelling when weighed against available treatments.
Survodutide has passed an important cardiovascular safety test. Making the treatment easier to continue may be its next major challenge.
Sources and Further Reading
- Bozkurt B, le Roux CW, Wharton S, et al. Cardiovascular Outcomes With Survodutide in Adults With Obesity at Increased Cardiovascular Risk (SYNCHRONIZE-CVOT): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, November 9, 2026.
- The Lancet — Original SYNCHRONIZE-CVOT Research Publication. DOI: 10.1016/S0140-6736(26)02140-9.
- Boehringer Ingelheim — SYNCHRONIZE-CVOT Trial Results Presented at AHA Scientific Sessions 2026. November 9, 2026.
- ClinicalTrials.gov — SYNCHRONIZE-CVOT Phase 3 Cardiovascular Outcomes Trial. NCT06077864.
- The New England Journal of Medicine — Survodutide Once Weekly for the Treatment of Adults With Obesity. June 7, 2026.
- The American Journal of Managed Care — Survodutide Meets Cardiovascular Safety End Point in SYNCHRONIZE-CVOT. November 9, 2026.
